# A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP

> **NCT06031844** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 24 (actual)

## Conditions studied

- Coronary Heart Disease

## Interventions

- **DRUG:** DFV890
- **DRUG:** DFV890 Placebo

## Key facts

- **NCT ID:** NCT06031844
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-16
- **Primary completion:** 2024-12-17
- **Final completion:** 2024-12-23
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06031844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06031844, "A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06031844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*